Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation

Significance Interaction between peptide–major histocompatibility complexes (pMHCs) and T cell receptors (TCRs) is the key mediator for tumor cell recognition by cytotoxic T cells. We performed a multimodal analysis on a prostate tissue antigen, PAP, to reveal peptides restricted by MHC I. Cognate TCRs were then isolated against those candidate targets. Information regarding both the epitopes and TCRs can be beneficial in designing new treatments for prostate cancer. Our platform can also be generalizable to other cancer antigens and different HLA types.

• Publication year

  2022

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2022-07-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.2203410119PMID 35878026PMCID 9351518
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Copyright 2022

  2022cited by this paper
• Tuning T cell receptor sensitivity through catch bond engineering

  2022cited by this paper
• Prostate cancer

  2021cited by this paper
• TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential

  2021cited by this paper
• Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning

  2021influential reference
• Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens

  2021cited by this paper
• HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses

  2021influential reference
• ARTEMIS: A Novel Mass-Spec Platform for HLA-Restricted Self and Disease-Associated Peptide Discovery

  2021influential reference
• Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

  2021cited by this paper
• Shared Antigen-specific CD8+ T cell Responses Against the SARS-COV-2 Spike Protein in HLA A*02:01 COVID-19 Participants

  2020cited by this paper
• Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

  2020cited by this paper
• Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.

  2020cited by this paper
• Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics

  2019cited by this paper
• The GTEx Consortium atlas of genetic regulatory effects across human tissues

  2019cited by this paper
• Comparison of the MHC I Immunopeptidome Repertoire of B‐Cell Lymphoblasts Using Two Isolation Methods

  2018cited by this paper
• The Immune Epitope Database (IEDB): 2018 update

  2018influential reference
• MHCflurry: Open-Source Class I MHC Binding Affinity Prediction.

  2018cited by this paper
• Generation of mature T cells from human hematopoietic stem/progenitor cells in artificial thymic organoids

  2017cited by this paper
• NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

  2017cited by this paper
• Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1

  2017cited by this paper
• Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction

  2017cited by this paper
• MHCflurry: open-source class I MHC binding affinity prediction

  2017cited by this paper
• Massively parallel digital transcriptional profiling of single cells

  2016cited by this paper
• Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

  2016cited by this paper
• CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

  2016cited by this paper
• CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

  2016cited by this paper
• Driving gene-engineered T cell immunotherapy of cancer

  2016influential reference
• Driving CAR T-cells forward

  2016cited by this paper
• CD 19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

  2016cited by this paper
• Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

  2014cited by this paper
• Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)

  2014cited by this paper
• Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

  2013cited by this paper
• Reassessing target antigens for adoptive T cell therapy

  2013cited by this paper
• Use of Mutated Self-Cleaving 2A Peptides as a Molecular Rheostat to Direct Simultaneous Formation of Membrane and Secreted Anti-HIV Immunoglobulins

  2012cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer

  2010cited by this paper
• Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

  2010cited by this paper
• Soluble plasma HLA peptidome as a potential source for cancer biomarkers

  2010cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• NetMHCpan, a method for MHC class I binding prediction beyond humans

  2008cited by this paper
• Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

  2008cited by this paper
• Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1

  2006cited by this paper
• Generation of peptide–MHC class I complexes through UV-mediated ligand exchange

  2006cited by this paper
• The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.

  2002cited by this paper
• Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.

  2001cited by this paper
• Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1

  2001cited by this paper
• Crystal structure of human prostatic acid phosphatase

  2000cited by this paper
• A new era for cancer immunotherapy based on the genes that encode cancer antigens.

  1999cited by this paper
• The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.

  1998cited by this paper
• Applications of network BLAST server.

  1996cited by this paper
• An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

  1996cited by this paper
• Structure of peptides associated with MHC class I molecules.

  1994cited by this paper
• Peptide-induced modulation of target cell sensitivity to natural killing.

  1992cited by this paper
• Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.

  1992cited by this paper
• HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation.

  1992cited by this paper
• Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases.

  1989influential reference
• Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

  1988cited by this paper
• Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers.

  1986cited by this paper
• The immunohistochemical detection of prostatic acid phosphatase: its possibilities and limitations in tumour histochemistry

  1981cited by this paper
• Journal of Translational Medicine Tumor Antigens for Cancer Immunotherapy: Therapeutic Potential of Xenogeneic Dna Vaccines

  year unknowncited by this paper

• TCR-based therapy directed against kallikrein-related peptidase 4 is safe and effective against prostate cancer.

  2025cites this paper
• Defining T cell receptor repertoires using nanovial-based binding and functional screening

  2024cites this paper
• Defining T cell receptor repertoires using nanovial-based affinity and functional screening

  2023influential citation
• Antigen discovery for the development of cancer immunotherapy.

  2023cites this paper
• IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing

  2023cites this paper